Alpha Teknova, Inc. (TKNO): Results of Operations and Financial Condition
Alpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Reports Second Quarter 2026 Financial Results Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek TM custom order configu
How this was made
The 30-second read
Why it matters
The key tradable items are the raised 2026 revenue guidance ($45-47M) and the revised full-year Free Cash Outflow outlook (<$8M), supported by Q2 revenue growth and improved cash usage versus the prior year.
Market read
For TKNO, the filing provides a fresh earnings-and-guidance datapoint plus a cash-flow outlook change that can drive immediate repricing.
What to watch
Gross margin improvement is partly tied to faster inventory turns and prior-year manufacturing efficiency comparisons, so investors may scrutinize sustainability of margins and cash conversion.
Background
This is an SEC Form 8-K (Item 2.02) with Teknova’s Q2 2026 financial results and updated 2026 outlook, plus a product/technology update (Build-Tek AI configurator).
Ticker impact
Teknova reported Q2 2026 revenue of $12.2M (+18% YoY) and raised 2026 revenue guidance to $45-47M while expecting Free Cash Outflow < $8M.
Likely upward bias for TKNO on open, with follow-through dependent on investor reaction to the AI Build-Tek launch and cash-flow trajectory.
The filing discloses fresh, decision-relevant numbers: Q2 results, raised full-year revenue range, and a revised full-year Free Cash Outflow expectation.
Market effects
Signals demand recovery and improving operating leverage in life-science reagents, potentially supporting sentiment for small-cap biotech supply-chain names.
Limited, company-specific impact likely confined to US small-cap biotech supply-chain investors.
Low; no direct global macro or cross-border transaction disclosed.
Counterpoint
Raised revenue guidance may still be accompanied by continued cash burn, so the market could focus on whether Free Cash Outflow improvement is durable beyond 2026.
Key entities
- public_companyAlpha Teknova, Inc.
Nasdaq-listed life-science reagents producer reporting Q2 2026 results and raising 2026 revenue guidance.
- productBuild-Tek
AI-powered custom order configurator launched after a beta release, aimed at speeding preclinical to clinical manufacturing workflows.
- eventSidoti Microcap Conference (Virtual)
Investor conference scheduled for Aug 19-20, 2026, potentially adding near-term visibility for TKNO.
